158818-29-2

Upstream product

• 5326-87-4 N-(phenyl)bromoacetamide 
• 16836-95-6 silver(I) 4-methylbenzenesulfonate 
• 54150-49-1 2-chloro-2-oxoethyl 4-methylbenzenesulfonate 
• 98-59-9 p-toluenesulfonyl chloride 
• 39794-77-9 2-(4-methylphenyl)sulfonyloxyacetic acid 
• 39794-75-7 ethyl α-p-toluenesulfonyloxyacetate 
• 62-53-3 aniline 

Downstream Products

• 4746-61-6 glycolanilide 
• 3759-90-8 3-Phenyl-1,3-oxazolidin-2,4-dion 

Relevant academic research and scientific papers

Electrochemical Studies on Haloamides. Part XII. Electrosynthesis of Oxazolidine-2,4-diones

Electrogenerated bases promote the carboxylation of NH-protic carboxamides bearing a leaving group at the position 2 to give oxazolidine-2,4-diones.The process is believed to involve acid-base reaction with the substrate, carboxylation of its conjugate base to corresponding carbamate and ring-closure following intramolecular SN2 reaction.A variety of oxazolidine-2,4-diones, including clinically used trimethadione and malidone, have been prepared in high to excellent yield, which established the scope and generality of this new ring-forming process.

SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growthinvitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents.

Tetraethylammonium hydrogen carbonate in organic synthesis: Synthesis of oxazolidine-2,4-diones

Oxazolidine-2,4-diones were synthesised by tetraethylammonium hydrogen (TEAHC) promoted carboxylation of secondary carboxamides bearing a leaving group at the α-position. Several oxazolidine-2,4-diones, including clinically used malidone, have been prepared in moderate to excellent yields as a results of a formal proton extraction-carboxylation- intramolecular S(N)2 one-pot sequence.